Skip to NavigationSkip to content

Novartis' CAR T therapy Kymriah nails main goal in follicular lymphoma

Published on 04/08/20 at 11:21am

Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL), revealing that the therapy met its primary its primary endpoint of complete response rate (CRR) in Phase 2 trials, according to an independent review committee.

The findings are significant for a treatment of this stature. Kymriah was the first CAR T therapy to secure approval from the FDA, and is currently authorised for use in the treatment of acute lymphoblastic leukaemia (ALL) and r/r adult diffuse large B-cell lymphoma (DLBCL) in patients up to 25 years of age.

The company said it continues to expand its manufacturing capacity for the therapy as it closes in on a third approved indication, with seven facilities across four continents contributing to the production of the drug worldwide.

“We are pleased that Kymriah is showing meaningful results and may provide a potentially definitive treatment option for patients with relapsed and refractory follicular lymphoma,” remarked Dr John Tsai, Head of Global Drug Development and Chief Medical Officer at Novartis. “These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments.”

Novartis confirmed that full results from the study would be revealed at a future medical event and that the data will be submitted to US and European regulators.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches